New application of far infrared ray with wavelength of 14 + / -10 [mu] m

Abstract

The present invention provides the use of far infrared rays having a wavelength of 14 + / -10 [mu] m or a component capable of generating far infrared rays having a wavelength of 14 + / -10 [mu] m for the manufacture of a device for the treatment and / or prevention of inflammatory occlusive vascular diseases. According to the mode, excessive inflammation of the diseases can be inhibited, blood flow rheology can be changed, and blood perfusion can be improved.

Description

Technical Field

[0001] The present invention relates to the field of medical devices, and in particular to a far-infrared therapeutic device with a specific wavelength and its application in treating inflammatory occlusive and / or stenotic vascular diseases. Background Art

[0002] Inflammatory vascular disease, including giant cell arteritis, thromboangiitis obliterans, rheumatic arteritis, infectious arteritis, syphilitic arteritis, and atherosclerosis-related diseases [1] Etc. Among them, the causes include autoimmune imbalance, microbial infection, lipid metabolism disorder, etc. [2] The common characteristics are inflammatory changes in blood vessels and / or surrounding tissues, stenosis or dilation of the vascular lumen, and ischemic or hemorrhagic consequences. [3] Among them, vascular stenosis or even occlusion leading to ischemic pathological changes is particularly common, with limited conventional treatment and poor prognosis. [4,5] .

[0003] Thromboangiitis obliterans (TAO) is an inflammatory, segmental, thrombotic, occlusive peripheral vascular disease that often affects the small and medium-sized blood vessels in the limbs of young smokers, and occasionally affects the visceral blood vessels. It is a representative of inflammatory vascular diseases. [6] The clinical manifestations begin with ischemic symptoms caused by stenosis or occlusion of distal arterioles and veins. As the disease progresses, intermittent claudication, rest pain, migratory thrombophlebitis and skin ulcers may occur, and even limb ischemia and necrosis may require amputation. The causes and mechanisms of thromboangiitis obliterans are complex and unclear. Current studies have found that risk factors include smoking, immune inflammatory mediators, infection, genetics, homocysteine, NIRP3 inflammasomes, etc. [7] Smoking is considered to be one of the most likely inducing factors. There are currently three hypotheses on the pathogenesis of the disease. The first is that excessive oxidative stress mediates vascular endothelial damage, which is particularly evident in smoking patients. [8,9] The second hypothesis is that it is an autoimmune disease. In the acute phase, immune cells (CD4+, CD8+ and macrophages) and circulating autoreactive antibodies (AECA, ANCA) were found in the vascular endothelium, and the cytokines IL-1β, IL-4, IL-17a and IL-23 in the blood were also significantly increased. [10,11] The third is the theory of blood flow rheology changes. In patients with thromboangiitis obliterans, the non-endothelial-dependent vasoconstriction function is enhanced and the blood is in a state of hypercoagulation, which is a high-risk factor for thrombosis. [12,13] Patients with thromboangiitis obliterans often have typical pathological features

[14] :The affected blood vessels show inflammatory cell infiltration of the vessel wall accompanied by luminal thrombosis. The acute phase of thromboangiitis obliterans pathological manifestations are highly cellular inflammatory thrombi, and the stable phase is characterized by arterial and venous thrombosis, but the structural integrity of the vascular middle layer and intima is not damaged.

[0004] Thromboangiitis obliterans is a chronic, progressive vascular inflammatory disease for which there is currently no radical treatment. Currently, there are six types of treatments: 1) General treatment: Strictly quit smoking and increase exercise

[15] , this treatment requires long-term persistence and can only reduce the probability of disease onset. The therapeutic effect is extremely limited when combined with other treatment methods; 2) Drug treatment, mainly antithrombolytic drugs, vasodilators, immunosuppression, analgesia and antibiotics. Currently, drug treatment can only delay the progression of the disease and cannot effectively cure it.

[16] , and this type of drug has the risk of causing bleeding, and some drugs can only play a symptomatic treatment role; 3) Surgical treatment, mainly including bypass surgery, sympathetic ganglionectomy, stem cell transplantation, radiofrequency ablation, tibial transverse bone transfer and other treatment methods [17,18] ; 4) Intraluminal interventional therapy: percutaneous transluminal angioplasty, intraluminal stent placement, intraluminal thermal ablation and intraluminal intimal plaque resection

[19] At present, the most commonly used treatment methods are interventional surgery and bypass surgery. Although blood flow can be restored in time, they face problems such as surgical trauma and low long-term patency rate. Stem cell transplantation faces problems with cell sources and controllability of cell differentiation. The cost of surgical treatment is high and there is trauma, and some surgical plans are more traumatic; 5) Traditional Chinese medicine treatment: The ancient medical book "Lingshu·Carbuncle" has long been recorded as "gangrene", and the dialectical treatment classification is not unified. There are internal treatments with traditional Chinese medicine, acupuncture treatment, and external treatments such as scalding, external washing, and external application for treatment.

[20] Although the treatment history is long and there are many methods, there are problems such as large differences in treatment effects and instability; 6) Hyperbaric oxygen therapy: increasing the oxygen concentration in the body, improving tissue oxygen supply, and helping to relieve ischemic symptoms, but this program requires large specific equipment and has risks such as oxygen poisoning and oxygen pressure injury.

[21] , and it can only temporarily improve the symptoms.

[0005] Although there are a wide variety of treatments, the risk of amputation for patients with thromboangiitis obliterans is 25% 5 years after diagnosis, 38% 10 years after diagnosis, and 46% 20 years after diagnosis. It is the second leading cause of amputation in young people (less than 45 years old), bringing serious burdens to individuals and society.

[22] Although there are various treatment methods at present, there is no method that can completely cure the disease because the cause is unknown, the course of the disease is prone to recurrence, and it continues to progress and worsen. The overall treatment effect is not ideal. Therefore, there is an urgent need to explore a treatment method that can be repeated, can inhibit inflammation, has little trauma, and has low risk.

[0006] Far infrared is generally considered to be a region of the infrared spectrum with a wavelength of 3μm to 1000μm. Compared with other infrared spectra, it has the strongest penetrating power and the smallest heat generation effect.

[23] Far infrared rays can transfer energy between objects through thermal radiation. As the wavelength of light increases, its ability to penetrate human tissue also increases.

[24] Far infrared rays, under the premise of non-invasiveness, have good penetrating power and radiation power. The far infrared characteristics of human biological tissue output are 6-50μm far infrared rays, of which the far infrared rays with a wavelength of 8-14μm account for 46% of the total energy of human radiation.

[25] , and it is the best biophysical band for human tissue, and it is scientific and safe. At present, in medical clinical treatment, most of the far-infrared wavelengths used are 3-25μm, which can prevent or relieve the pain, stiffness and fatigue of rheumatoid arthritis and ankylosing spondylitis, treat ophthalmic, neurological and psychiatric diseases, and stimulate the proliferation and repair of mesenchymal stem cells and heart cells, improve the symptoms of long-term new crown, etc. [26-30] .

[0007] However, there is no application of far infrared rays of a specific wavelength (14±10 μm) to treat thromboangiitis obliterans. For the clinical treatment of thromboangiitis obliterans, the current treatment options for thromboangiitis obliterans are limited, the effects are poor, and the disease often recurs and progresses, resulting in a heavy burden of disease. Summary of the invention

[0008] The purpose of the present invention is to provide a green catalyst for promoting the pyrolysis or gasification of mixed biomass to prepare hydrogen-rich fuel gas, and a preparation method and application thereof, in order to solve the above technical problems.

[0009] According to one aspect of the present invention, there is provided use of far infrared rays having a wavelength of 14±10 μm or a component capable of generating far infrared rays having a wavelength of 14±10 μm in preparing a device for treating and / or preventing inflammatory occlusive vascular diseases.

[0010] Preferably, the inflammatory occlusive vascular disease is thromboangiitis obliterans.

[0011] Preferably, the treatment method is to directly irradiate the affected limb through air.

[0012] Preferably, the irradiation time is 10-30 minutes.

[0013] According to another aspect of the present invention, there is provided the use of far infrared rays with a wavelength of 14±10 μm or components capable of generating far infrared rays with a wavelength of 14±10 μm in preparing a device for reducing the whole blood low shear value or the red blood cell aggregation index.

[0014] According to the technical solution provided by the present invention, the device of far infrared rays of specific wavelength (14±10 μm) has the advantages of safety, effectiveness, non-invasiveness and economy for the prevention and treatment of thromboangiitis obliterans, so it will have good application value and prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of this application. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0016] Figure 1 The overall therapeutic effect of FIR on thromboangiitis obliterans (TAO) rats was demonstrated. In the SD rat animal model, the appearance of the sham operation group (Sham), thromboangiitis obliterans group (TAO) and far infrared treatment group [TAO+FIR] was compared and found ( Figure 1 A): After FIR irradiation treatment, the gangrene degree of the left hind limb (lesioned limb) of TAO rats was reduced, and both males and females had positive effects; and the quantitative pathological score statistical analysis showed that ( Figure 1 B and C). At the end of the study (15 days), the pathological scores of both sexes in the TAO+FIR group were significantly lower than those in the TAO group, and the severity was reduced; it also improved the degree of weight loss ( Figure 1 D and E). Among them, * is compared with the rats in the Sham group, and # is compared with the rats in the TAO group.

[0017] Figure 2 The figure shows the effect of FIR on the improvement of ischemic hindlimb blood circulation in TAO rats. In the SD rat animal model, the microcirculatory blood flow meter was used to monitor the blood perfusion of the hindlimbs in the sham operation group (Sham), thromboangiitis obliterans group (TAO) and far infrared treatment group [(TAO+FIR]). Figure 2 A) found that compared with the TAO group, the left hind limb blood flow of male and female ischemic rats in the TAO+FIR group was improved; and the statistical analysis of the left hind limb blood flow value / right hind limb blood flow value percentage (blood flow%, L / R) showed that ( Figure 2 B and C ), at the study endpoint (15 days), the blood flow percentage in the TAO+FIR group was increased compared with the TAO group in both sexes, and it was statistically significant.

[0018] Figure 3 The figure shows the inhibitory effect of FIR on inflammation in TAO rats. In the SD rat animal model, at the end of the experiment (15 days), the left hind limb artery and blood of the three groups of Sham, TAO and TAO+FIR were tested. The artery was pathologically sectioned and stained with H&E and found that ( Figure 3A), compared with the TAO group, the inflammatory response of the vascular tissue and surrounding tissues of the ischemic limbs in the TAO+FIR group was alleviated, the lumen was enlarged, and the thrombus was sparse; after statistical analysis of the erythrocyte sedimentation rate K value of the whole blood, it was found that ( Figure 3 B): The ESR K value of TAO group was higher than that of Sham group (healthy group), while the ESR K value of TAO+FIR group was lower than that of TAO group after FIR irradiation treatment. This proves that FIR can inhibit the inflammation of local vascular tissue and blood circulation in TAO rats.

[0019] Figure 4 The effect of FIR on the blood rheology of TAO rats is shown in the figure. After testing the whole blood and plasma of rats using a liquid rheology detector, it was found that the whole blood high shear value and red blood cell deformation index ( Figure 4 A and B) There was no change in the Sham group, TAO group, and TAO+FIR, while the whole blood cut-off value related to medium and small blood vessels ( Figure 4 C) was increased in TAO but not decreased after FIR treatment; whereas in whole blood low shear value and red cell aggregation index parameters related to small diameter vessels ( Figure 4 D and E), the TAO group was higher than the Sham group, while the FIR+TAO group was lower than the TAO group, which is consistent with the anatomical location of TAO mainly in small vessel lesions. Similarly, FIR has no significant effect on TAO plasma viscosity related indicators ( Figure 4 F and G) Plasma viscosity and fibrinogen also decrease. FIR acts on TAO-related blood flow rheological parameters, thereby reducing the risk of thrombosis.

[0020] Figure 5 The lower limb computed tomography artery reconstruction images (CTA) of TAO patients before treatment were shown. Lower limb CTA showed that Case 1 and Case 2 both had staged lesions of small and medium-sized blood vessels below the knee, and Case 3 had lesions of both lower limb arteries, involving occlusion of the left femoral artery with collateral artery formation.

[0021] Figure 6 The therapeutic effect of FIR on clinical TAO patients is shown. In TAO patients, FIR (14μm) was used to irradiate both lower limbs (including patients with lesions in the left and right limbs and both lower limbs at the same time). After 6 months of follow-up, blood perfusion increased significantly, the ankle-brachial index (ABI) of the affected limb of the patient basically returned to normal, the pain was significantly relieved, the visualized pain score was reduced, and the absolute claudication distance was extended by more than 3.5 kilometers. The overall clinical stage was improved to above stage IIa. It is proved that FIR (14μm) has the effect of improving the treatment effect on TAO patients. DETAILED DESCRIPTION

[0022] Although the present invention can be implemented in many different forms, what is disclosed here is its specific illustrative embodiment that verifies the principle of the present invention.It should be emphasized that the present invention is not limited to the specific embodiment illustrated.In addition, any section title used herein is only for organizational purposes and is not to be interpreted as limiting the subject matter described.

[0023] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention will have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context requires otherwise, terms in the singular shall include plural forms, and terms in the plural shall include singular forms. More specifically, as used in this specification and the appended claims, the singular forms "a", "a class" and "the" include plural indicators unless the context clearly indicates otherwise. Thus, for example, reference to "a class of diseases" includes multiple diseases; reference to "an animal" includes multiple stages and states of animals, etc. In this application, unless otherwise stated, the use of "or" means "and / or". In addition, the use of the term "comprising" and other forms (such as "including" and "containing") is not restrictive. In addition, the ranges provided in the specification and the appended claims include all values ​​between the endpoints and breakpoints.

[0024] Generally, the terms and techniques related to the animal models and tissue culture, molecular biology, immunology, pathological histology, genetics and clinical diagnosis and treatment described herein are well-known and commonly used in the art. Unless otherwise indicated, the methods and techniques of the present invention are generally performed according to conventional methods known in the art.

[0025] The following examples are provided to allow those skilled in the art to more clearly understand the present invention. It should be noted that the following examples do not limit the scope of protection claimed in the present invention and are only illustrative examples. The raw materials, reagents or devices mentioned in the following examples, unless otherwise specified, can be obtained from commercial sources or by known existing methods.

[0026] Example 1

[0027] The therapeutic effect of FIR on the whole body of rats with thromboangiitis obliterans (TAO).

[0028] SPF male Sprague Dawley (SD) rats weighing 220±20g were randomly divided into three groups: sham operation group (Sham), thromboangiitis obliterans group (TAO) and far infrared treatment group [(TAO+FIR]. After intraperitoneal injection of 2% sodium pentobarbital for anesthesia and hair removal, the rats were placed in a supine position, and a 1 cm oblique incision was made at the midpoint of the left groin. The subcutaneous tissue and muscle tissue were bluntly separated to expose the femoral artery sheath. The upper segment of the superficial epigastric artery was freed, and the length of the femoral artery was 0.5 cm, blood flow was blocked at the proximal end with a blood vessel, 0.1 ml of sodium laurate solution (Source Leaf Biological, 10 g / L, the solvent is normal saline) was injected into the distal end, and then a cotton ball was used to press the puncture point to stop bleeding. Fifteen minutes later, check that there is no bleeding at the puncture site and the skin can be sutured. After the operation, 400,000 units of penicillin were injected intraperitoneally to prevent infection; after modeling, the rat's left hind limb showed ischemic symptoms, such as pale cyanosis of the skin, decreased skin temperature, gangrene, shedding, etc., indicating that the modeling was successful, see Figure 1 A Photo of the hind limbs of the TAO group. The sham group (Sham) was injected with 0.1 ml of saline into the femoral artery as a healthy control group. Similarly, 200±20g female Sprague Dawley (SD) rats were grouped and modeled in the same way.

[0029] Animal intervention: The animals were kept in a temperature-controlled room with a 12-hour light / dark cycle and given free access to food and water. All experiments were conducted in accordance with the Institutional Animal Care and User Committee Guidelines of the Macau University of Science and Technology. After the far-infrared therapy group [(TAO+FIR] was fixed, the affected limb (left hind limb) was irradiated with a 14μm far-infrared irradiator for 30 minutes twice a day, with an interval of 6 hours, and the irradiation distance was about 3cm for 15 consecutive days. The sham group and the TAO group were given the same fixed movements and fixed time every day, without far-infrared irradiation.

[0030] Equipment for FIR irradiation treatment: FIR vascular irradiator; parameters: output wavelength 14±10μm, operating voltage 3.7V, power output 1W, operating temperature range 15-35℃, far infrared total emissivity not less than 0.80.

[0031] Pathological scoring and weight monitoring: Pathological scoring and weight measurement of the affected limb were recorded on day 0 (the day of surgery), and on days 1, 3, 6, 9, 12, and 15 after surgery. Figure 1 B. Figure 1 C. Figure 1 D. Figure 1E; After FIR irradiation treatment, the degree of gangrene in the left hind limb (lesioned limb) of TAO rats was alleviated, with positive effects in both males and females; and the statistical analysis of quantitative pathological scores showed that at the end of the study (15 days), the pathological scores of both sexes in the TAO+FIR group were significantly lower than those in the TAO group, and the severity was reduced; it could also improve the degree of weight loss caused by the disease.

[0032] Example 2

[0033] The improving effect of FIR on the blood circulation of ischemic hindlimbs in TAO rats.

[0034] The TAO rat model was established and treated with FIR irradiation using the same method as above.

[0035] At the end of the experiment (day 15), the rats were anesthetized to a satisfactory degree and placed in a supine position on the test table. After the PeriCam PSI NR (Parry, Sweden) scanning head was adjusted to a fixed height, the laser speckle contrast analysis technology was used to take pictures and scan the lower abdomen and lower limbs of the rats. The stable segment file of the blood perfusion value was obtained, and the region of interest (ROI) was circled in the same position and range of the lower limbs. The blood perfusion value (Perfusion, AU) of the corresponding area was then obtained, and the percentage of the left lower limb blood perfusion value / right lower limb blood perfusion value was statistically analyzed ( Figure 2 B) Figure 2 It can be found that compared with the TAO group, the left hind limb blood flow of male and female ischemic rats in the TAO+FIR group was improved; and the statistical analysis of the left hind limb blood flow value / right hind limb blood flow value percentage (blood flow%, L / R) showed that ( Figure 2 B and C), at the study endpoint (15 days), the blood flow percentage in the TAO+FIR group was increased compared with the TAO group in both sexes, and it was statistically significant.

[0036] Example 3

[0037] Inhibitory effect of FIR on inflammation in TAO rats

[0038] The TAO rat model was established and treated with FIR irradiation using the same method as above.

[0039] At the end of the laboratory (5th day), the vascular tissue of the left hind limb was taken, added to pre-cooled physiological saline to clean the residual blood, and after absorbing the excess water, it was immediately immersed in 4% paraformaldehyde (PFA) for tissue fixation for 24 hours. The fixed tissue blocks were placed in different concentration gradient ethanol solutions for dehydration, then immersed in xylene for transparency, and then immersed in an equal amount of melted paraffin and xylene. Then, cold fixation, embedding, 5μm thick sections were cut on a microtome, and then dewaxing and hydration were performed. The hydrated sections were placed in hematoxylin and 1% eosin solution for staining, and finally photographed under an ordinary optical microscope (such as Figure 3 A). At the same time, 2 mL of arterial blood was taken into the anticoagulation tube for anticoagulation treatment. The parameters of the blood rheometer (Zibo Hengtuo, HT-100B) were set as follows: A coefficient: 947, B coefficient: 1082. The anticoagulation tubes were placed in the automatic loading platform according to the set order. The erythrocyte sedimentation rate K value and other blood rheology indicators were tested and statistical analysis was performed. Figure 3 B. By Figure 3 It was found that compared with the TAO group, the inflammatory response of the vascular tissue and surrounding tissues in the ischemic limbs of the TAO+FIR group was alleviated, the lumen was enlarged, and the thrombus was sparse; the ESR K value of TAO was higher than that of the Sham group (healthy group), and after FIR irradiation treatment, the ESR K value of the TAO+FIR group was lower than that of the TAO group. This proves that FIR can inhibit the inflammation of the local vascular tissue and blood circulation in TAO rats.

[0040] Example 4

[0041] Effects of FIR on hemorheology in TAO rats

[0042] The TAO rat model was established and treated with FIR irradiation using the same method as above.

[0043] The symptoms selected in this embodiment include whole blood high shear value and red blood cell deformation index related to large and medium diameter blood vessels, whole blood medium shear value related to small and medium blood vessels, whole blood low shear value and red blood cell aggregation index related to small diameter blood vessels. Its theoretical basis is derived from the basic principles of hemodynamics and hemorheology, which explain the influence of different blood vessel diameters on blood flow characteristics. Specifically: in large and medium diameter blood vessels, the blood flow velocity is faster and the shear stress (Shear Stress) is higher. At this time, the blood exhibits a behavior closer to that of a Newtonian fluid, and the deformability of red blood cells becomes a key factor affecting blood viscosity. Red blood cells need to deform under high shear stress to adapt to rapid flow. Good red blood cell deformability can reduce blood viscosity, thereby improving the hemodynamic performance of large and medium blood vessels.

[0044] In small and medium diameter blood vessels, blood flow velocity and shear stress are between high shear and low shear. At this time, the non-Newtonian fluid characteristics of blood are more obvious, and blood viscosity is affected by both plasma and red blood cell components. The medium shear value reflects the fluidity of blood at medium shear rates and is a key indicator for evaluating the hemodynamic characteristics of small and medium blood vessels.

[0045] In small-diameter blood vessels, the blood flow velocity is slower and the shear stress is lower. At this time, the non-Newtonian properties of the blood are significantly enhanced, and red blood cell aggregation and deaggregation become the main factors determining blood flow resistance. Under low shear stress, red blood cells are more likely to aggregate to form a "coin-like" structure, which will significantly increase blood viscosity and lead to increased blood flow resistance. The low shear value reflects the viscosity level of blood at low shear rates and is a key parameter for evaluating small blood vessel microcirculation disorders. The analysis of these parameters can provide a strong basis for the diagnosis and monitoring of diseases with abnormal hemodynamics.

[0046] In this example, 2 mL of arterial blood was taken and placed in an anticoagulation tube for anticoagulation treatment. The blood rheometer (Zibo Hengtuo, HT-100B) was set with the following parameters: A coefficient: 947, B coefficient: 1082. The anticoagulation tubes were placed in the fully automatic loading platform in the set order to detect the erythrocyte sedimentation K value and other blood rheology indicators. By analyzing the three major indicators that affect thrombosis, blood cell deformability, aggregation and plasma viscosity, it was found that: Large and medium diameter blood vessels Whole blood high shear value and red blood cell deformation index ( Figure 4 A and B) There was no change in the Sham group, TAO group, and TAO+FIR, but Whole blood related to small and medium vessels Median cut value( Figure 4 C) was increased in TAO but not decreased after FIR treatment; whereas in whole blood low shear value and red cell aggregation index parameters related to small diameter vessels ( Figure 4 D and E), the TAO group was higher than the Sham group, while the FIR+TAO group was lower than the TAO group, which is consistent with the anatomical location of TAO mainly in small vessel lesions. Similarly, FIR has no significant effect on TAO plasma viscosity related indicators ( Figure 4 F and G) plasma viscosity and fibrinogen also decreased. FIR has a positive effect on TAO-related hemorheological parameters, thereby reducing the risk of thrombosis.

[0047] Example 5

[0048] Clinical therapeutic effect of FIR on patients with TAO

[0049] TAO patients were from the Affiliated Hospital of Southwest Medical University, a clinical research cooperation unit. As shown in Table 1 , the patients were young men between 19 and 30 years old, with a disease course of 1 to 3 years and clinical stages of IIb and IV. Figure 5The computed tomography artery reconstruction images (CTA) of the lower limbs of TAO patients before treatment showed that both Case 1 and Case 2 had staged lesions of small and medium-sized blood vessels below the knee. Case 3 had lesions in both lower limb arteries, involving occlusion of the left femoral artery with collateral artery formation.

[0050] Table 1

[0051] Case 1 Case 2 Case 3 Patient age (years) 30 19 21 gender male male male Course of disease 1 year 1 3 years Clinical staging IIb IV IIb

[0052] In TAO patients, FIR was used to irradiate both lower limbs (including patients with lesions in the left and right limbs and both lower limbs at the same time). On the basis of combined basic treatment, a far-infrared irradiation device that generates 14μm was used to continuously irradiate the vascular lesions in the affected limbs of the patient, 30 minutes each time, twice a day.

[0053] like Figure 6 As shown in the figure, after 6 months of follow-up, blood perfusion increased significantly, the ankle brachial index (ABI) of the affected limb of the patient basically returned to normal, the pain was significantly relieved, the visual pain score was reduced, and the absolute claudication distance was extended by more than 3.5 kilometers. The overall clinical stage was improved to stage IIa and above. It proves that FIR has the effect of improving the treatment effect of TAO patients.

[0054] In summary, FIR can inhibit excessive inflammation in TAO and improve blood rheology indicators, reduce the possibility of thrombosis, improve blood perfusion of the affected limb, and play a good therapeutic role in thromboangiitis obliterans through this mechanism. It can also be applied to other inflammatory occlusive vascular diseases.

[0055] The purpose of the present invention is to use far infrared rays with a wavelength of 14±10 μm to improve the blood circulation of TAO affected limbs and inhibit inflammation in the body, especially to reduce the whole blood low shear value and red blood cell aggregation index parameters related to small diameter blood vessels, so as to achieve the treatment and / or prevention of inflammatory occlusive vascular diseases. Specifically, the present invention first provides a use of far infrared rays with a wavelength of 14±10 μm or a component capable of generating far infrared rays with a wavelength of 14±10 μm in the preparation of a product, wherein the product is used to treat and / or prevent inflammatory occlusive vascular diseases, and reduce the whole blood low shear value or the red blood cell aggregation index.

[0056] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

[0057] References:

[0058] [1]ROY P,ORECCHIONI M,LEY K.How the immune system shapesatherosclerosis:roles of innate and adaptive immunity[J].Nat Rev Immunol,2022,22(4):251-65.

[0059] [2]MICHAILIDOU D,ZHANG T,STAMATIS P,et al.Risk of venous and arterialthromboembolismin patients with giant cell arteritis and / or polymyalgiarheumatica:A Veterans Health Administration population-based study in theUnited States[J].J Intern Med,2022,291(5):665-75.

[0060] [3]ZHU K,LV F,HOU X,et al.Thrombosis in vasculitis:An updated reviewof etiology,pathophysiology,and treatment[J].Heliyon,2024,10(12):e30615.

[0061] [4]GALYFOS G,LIAKOPOULOSD,CHAMZIN A,et al.A systematic review andmeta-analysis of early and late outcomes after endovascular angioplasty amongpatients with thromboangiitis obliterans and chronic limb ischemia[J].J VascSurg,2023,77(5):1534-41.e2.

[0062] [5]CACIONE D G,MACEDO C R,DO CARMO NOVAES F,et al.Pharmacologicaltreatment for Buerger's disease[J].Cochrane Database Syst Rev,2020,5(5):CD011033.

[0063] [6]DARGON P T,LANDRY G J.Buerger's disease[J].Ann Vasc Surg,2012,26(6):871-80.

[0064] [7]LI M D,WANG Y F,YANG M W,et al.Risk Factors,Mechanisms andTreatments of Thromboangiitis Obliterans:An Overview of Recent Research[J].Curr Med Chem,2020,27(35):6057-72.

[0065] [8]ALIEE A,ZAHEDI AVVAL F,TAHERI H,et al.The Status of Nitric Oxideand its Backup,Heme Oxygenase 1,in Thromboangiitis Obliterans[J].Rep BiochemMol Biol,2018,6(2):197-202.

[0066] [9]MORROW J D,FREI B,LONGMIRE A W,et al.Increase in circulatingproducts of lipid peroxidation(F2-isoprostanes)in smokers.Smoking as a causeof oxidative damage[J].N Engl J Med,1995,332(18):1198-203.

[0067]

[10] KETHA S S,COOPER L T.The role of autoimmunity in thromboangiitisobliterans(Buerger's disease)[J].Ann N Y Acad Sci,2013,1285:15-25.

[0068]

[11] DELLALIBERA-JOVILIANO R,JOVILIANO E E,SILVA J S,et al.Activationof cytokines corroborate with development of inflammation and autoimmunity inthromboangiitis obliterans patients[J].Clin Exp Immunol,2012,170(1):28-35.

[0069]

[12] FUJII Y,FUJIMURA N,MIKAMI S,et al.Flow-mediated vasodilation isaugmented in a corkscrew collateral artery compared with that in a nativeartery in patients with thromboangiitis obliterans(Buerger disease)[J].Journal of vascular surgery,2011,54(6):1689-97.

[0070]

[13] DELLALIBERA-JOVILIANO R,JOVILIANO E E, P RB.Determination of kininogens levels and kallikrein / kininase II activities inpatients with thromboangiitis obliterans[J].Scandinavian journal ofimmunology,2010,72(2):128-33.

[0071]

[14] PUECHAL

[0072]

[15] Zhang Ting, Tang Wei, Guo Jia. Research progress on the application of exercise training and its improvement under professional guidance in patients with peripheral arterial disease[J]. Journal of Interventional Radiology, 2022, 31(09): 927-31.

[0073]

[16] HUANG ZH,KUO SY,CHIU YH,et al.Treatment of multiple refractoryankle ulcerations in thromboangiitis obliterans:A case report[J].Medicine,2018,97(20):e10798.

[0074]

[17] YUSOFF FM,KAJIKAWA M,TAKAEKO Y,et al.Long-term clinical outcomes of autologous bone marrow mononuclear cell implantation in patients with severe thromboangiitis obliterans[J].Circulation Journal,2020,84(4):650-5.

[0075]

[18] MARTIN-RUFINO JD, LOZANO FS, REDONDO AM, et al. Sequentialintravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease) [J]. Stem Cell Research & Therapy, 2018, 9: 1-6.

[0076]

[19] LEE CY,CHOI K,KWON H,et al.Outcomes of endovascular treatmentversus bypass surgery for critical limb ischemia in patients with thromboangiitis obliterans[J].PLoS One,2018,13(10):e0205305.

[0077]

[20] Chen Liqiang, Wu Erli, Zhang Jiayong. Overview of traditional Chinese medicine treatment of thromboangiitis obliterans[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2021, 30(07): 788-93.

[0078]

[21] Yang Wenping. Experience of comprehensive hyperbaric oxygen therapy for advanced thromboangiitis obliterans; proceedings of the Asia-Pacific Diving and Hyperbaric Medicine Academic Conference and the Second Cross-Strait Hyperbaric Oxygen Medicine Academic Conference, the 22nd National Hyperbaric Oxygen Medicine Academic Conference of the Chinese Medical Association, Qingdao, Shandong, China, F, 2013[C].

[0079]

[22] SOLIMAN M, MOWAFY K, ELSAADANY NA, et al. Thromboangiitisobliterans: Aggressive angioplasty provides a potential solution (randomizedpilot study) [J]. SAGE Open Med, 2020, 8: 2050312120927636.

[0080]

[23] VATANSEVER F, HAMBLIN M R. Far infrared radiation (FIR): Its biological effects and medical applications: Ferne Infrarotstrahlung: Biologische Effekte und medizinische Anwendungen[J]. Photonics&lasers inmedicine, 2012, 1(4): 255-66.

[0081]

[24] UDAGAWA Y,NAGASAWA H.Effects of far-infrared ray on reproduction,growth,behaviour and some physiological parameters in mice[J].In vivo(Athens,Greece),2000,14(2):321-6.

[0082]

[25] Lü Xiaoning, Li Minggao. Biological effects of far infrared rays and their clinical application in tissue repair[J]. Chinese Journal of Tissue Engineering Research and Clinical Rehabilitation, 2009, 13(46):9147-50.

[0083]

[26] CHIANG IN, PU YS, HUANG CY, et al. Far infrared radiation promotes rabbit renal proximal tubule cell proliferation and functional characteristics, and protects against cisplatin-induced nephrotoxicity[J]. PLoSOne, 2017, 12(7):e0180872.

[0084]

[27] CHIU HW, CHEN CH, CHANG JN, et al. Far-infrared promotes burnwound healing by suppressing NLRP3 inflammasome caused by enhanced autophagy[J]. Journal of Molecular Medicine, 2016,94:809-19.

[0085]

[28] CHANG Y.The effect of far infrared radiation therapy oninflammation regulation in lipopolysaccharide-induced peritonitis in mice[J].SAGE open medicine,2018,6:2050312118798941.

[0086]

[29] KHAN I,PATHAN S,LI X A,et al.Far infrared radiation induceschanges in gut microbiota and activates GPCRs in mice[J].Journal of AdvancedResearch,2020,22:145-52.

[0087]

[30] CHEN X,ZHANG H,ZENG W,et al.Far infrared irradiation suppressesexperimental arthritis in rats by down-regulation of genes involvedinflammatory response and autoimmunity[J].J Adv Res,2022,38:107-18.

Claims

1. Use of far infrared rays with a wavelength of 14±10 μm or components capable of generating far infrared rays with a wavelength of 14±10 μm in the preparation of a device for treating and / or preventing inflammatory occlusive vascular diseases.

2. The use according to claim 1, characterized in that The inflammatory occlusive vascular disease is thromboangiitis obliterans.

3. The use according to claim 1, characterized in that The treatment method is to directly irradiate the affected limb through the air.

4. The use according to claim 3, characterized in that The irradiation time is 10-30 minutes.

5. Use of far infrared rays with a wavelength of 14±10 μm or components capable of generating far infrared rays with a wavelength of 14±10 μm in the preparation of a device for reducing the low shear value of whole blood or the red blood cell aggregation index.

Images